Surgical treatment following neoadjuvant chemoradiotherapy in locally advanced rectal cancer

Colorectal cancer is a major public health problem worldwide, and locally advanced rectal cancer (LARC) is known for its poor prognosis. A multimodal treatment approach is the only method to achieve satisfactory local recurrence and survival rates in LARC. Determining which therapeutic modality for...

Full description

Saved in:
Bibliographic Details
Published inThe Kaohsiung journal of medical sciences Vol. 36; no. 3; pp. 152 - 159
Main Authors Huang, Ming‐Yii, Huang, Ching‐Wen, Wang, Jaw‐Yuan
Format Journal Article
LanguageEnglish
Published BP, Asia Wiley Publishing Asia Pty Ltd 01.03.2020
John Wiley & Sons, Inc
Wiley
Subjects
Online AccessGet full text
ISSN1607-551X
2410-8650
2410-8650
DOI10.1002/kjm2.12161

Cover

Loading…
More Information
Summary:Colorectal cancer is a major public health problem worldwide, and locally advanced rectal cancer (LARC) is known for its poor prognosis. A multimodal treatment approach is the only method to achieve satisfactory local recurrence and survival rates in LARC. Determining which therapeutic modality for LARC has the most satisfactory influence on quality of life and disease outcome is still controversial. LARC treatment is subject to continuous advancement due to the development of new and better diagnostic tools, radiotherapy techniques, and chemotherapeutic agents. Herein, we review various therapeutic modalities for LARC from several aspects. In addition to radiotherapy techniques such as neoadjuvant chemoradiotherapy (NCRT), we discuss the progress of chemotherapy, appropriate time interval between NCRT and surgery, relationship between tumor location and NCRT efficacy/safety, wait‐and‐watch policy, and predictors of treatment response following NCRT. Because of the controversies and unanswered questions regarding NCRT treatments for LARC, additional investigations are required to determine which therapeutic approach is the most feasible for LARC patients.
Bibliography:Funding information
Kaohsiung Medical University, Grant/Award Number: KMU‐TC108A04; Kaohsiung Medical University Chung‐Ho Memorial Hospital, Grant/Award Numbers: KMUH107‐7R28, KMUH107‐7R29, KMUH107‐7R30, KMUH107‐7R73, KMUH107‐7M22, KMUH107‐7M23, KMUHS10701, KMUHS10801, KMUHS10804, KMUHS10807; Taiwan Precision Medicine Initiative and Biomarker Discovery in Major Diseases of Taiwan Project, Grant/Award Number: AS‐BD‐108‐1; Ministry of Health and Welfare, Grant/Award Numbers: MOHW107‐TDU‐B‐212‐123006, MOHW107‐TDU‐B‐212‐114026B, MOHW108‐TDU‐B‐212‐114026, MOHW108‐TDU‐B‐212‐133006; Ministry of Science and Technology, Grant/Award Numbers: MOST108‐2321‐B‐037‐001, MOST108‐2314‐B‐037‐021‐MY3, MOST107‐2321‐B‐037‐003, MOST107‐2314‐B‐037‐116, MOST107‐2314‐B‐037‐022‐MY2, MOST107‐2314‐B‐037‐023‐MY2
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
ObjectType-Review-3
content type line 23
Funding information Kaohsiung Medical University, Grant/Award Number: KMU‐TC108A04; Kaohsiung Medical University Chung‐Ho Memorial Hospital, Grant/Award Numbers: KMUH107‐7R28, KMUH107‐7R29, KMUH107‐7R30, KMUH107‐7R73, KMUH107‐7M22, KMUH107‐7M23, KMUHS10701, KMUHS10801, KMUHS10804, KMUHS10807; Taiwan Precision Medicine Initiative and Biomarker Discovery in Major Diseases of Taiwan Project, Grant/Award Number: AS‐BD‐108‐1; Ministry of Health and Welfare, Grant/Award Numbers: MOHW107‐TDU‐B‐212‐123006, MOHW107‐TDU‐B‐212‐114026B, MOHW108‐TDU‐B‐212‐114026, MOHW108‐TDU‐B‐212‐133006; Ministry of Science and Technology, Grant/Award Numbers: MOST108‐2321‐B‐037‐001, MOST108‐2314‐B‐037‐021‐MY3, MOST107‐2321‐B‐037‐003, MOST107‐2314‐B‐037‐116, MOST107‐2314‐B‐037‐022‐MY2, MOST107‐2314‐B‐037‐023‐MY2
ISSN:1607-551X
2410-8650
2410-8650
DOI:10.1002/kjm2.12161